Health Trials

Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

3

Review clinical trials related to Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

To explore the efficacy of Iparomlimab and Tuvonralimab (QL1706) in combination with SOX chemotherapy versus chemotherapy alone for the neoadjuvant treatment of locally-progressed gastric/gastroesophageal union adenocarcinomas by evaluating the complete pathologic remission rate (pCR).

Participants needed: 96
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shandong Provincial HospitalUpdated: Apr 29, 2026Locations: 1
Eligibility criteria

Voluntary participation in the study and signing of informed consent; [+9]

Known HER2 positivity; [+22]

Read more
Status: Recruiting

Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

To evaluate the initial efficacy and safety of neoadjuvant low-dose interval radiotherapy combined with tirelizumab and SOX chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma.

Participants needed: 32
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shandong Provincial HospitalUpdated: Apr 29, 2026Locations: 1
Eligibility criteria

Patients voluntarily participated in the study and signed informed consent with... [+8]

a history of surgery for gastric/esophagogastric junction tumors; [+22]

Read more
Status: Not yet recruiting

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

This study is a prospective, multi-cohort clinical trial designed to evaluate the preliminary efficacy and safety of zanidatamab in combination with tislelizumab and chemotherapy/radiotherapy for patients with HER2-positive locally advanced or metastatic gastrointestinal tumors.

Participants needed: 70
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Tao ZhangUpdated: Nov 24, 2025
Eligibility criteria

Clinical diagnosis of gastric cancer and colorectal cancer [+26]

History of or concurrent other malignancies, except for basal cell carcinoma of... [+34]

Read more